Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 6:15 PM ET


Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studi...

175 Portland Street

4th Floor

Boston, MA 02114

United States

Founded in 2005

44 Employees



Key Executives for Zafgen, Inc.

Chief Executive Officer and Director
Age: 55
Total Annual Compensation: $425.0K
Age: 52
Total Annual Compensation: $195.4K
Chief Financial Officer
Age: 53
Total Annual Compensation: $297.9K
Chief Medical Officer
Age: 45
Total Annual Compensation: $407.0K
Chief Commercial Officer
Age: 52
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

Zafgen, Inc. Key Developments

Zafgen, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Zafgen, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, loss from operations was $19,717,000 against $14,361,000 a year ago. Net loss attributable to common stockholders was $19,884,000 or $0.73 per basic and diluted share against $14,689,000 or $0.65 per basic and diluted share a year ago. For nine months, loss from operations was $50,567,000 against $24,868,000 a year ago. Net loss attributable to common stockholders was $51,112,000 or $1.92 per basic and diluted share against $25,639,000 or $2.97 per basic and diluted share a year ago.

Zafgen, Inc., Q3 2015 Earnings Call, Nov 10, 2015

Zafgen, Inc., Q3 2015 Earnings Call, Nov 10, 2015

Khang & Khang LLP Files Securities Class Action Lawsuit against Zafgen, Inc

Khang & Khang LLP announced that a class action lawsuit has been filed against Zafgen, Inc. Investors who purchased or otherwise acquired shares between January 12, 2015 and October 16, 2015, inclusive (the 'Class Period') are encouraged to contact the Firm immediately to discuss their legal options. According to the complaint, on October 16, 2015, the company announced that the FDA had ordered a partial clinical hold on the company's Beloranib clinical trials following the death of a patient.

Similar Private Companies By Industry

Company Name Region
Vindico NanoBioTechnology, Inc. United States
Aridis Pharmaceuticals Inc. United States
Mergen Ltd. United States
Arkion Life Sciences, LLC United States
American Ag-Tec International, Ltd. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zafgen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at